Innovative Biologics
Anti-infective drug discovery and development company targeting microbes that produce pore-forming toxins.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
$2.3m | Grant | ||
| Total Funding | 000k | ||
Related Content
Established in 2003, Innovative Biologics, Inc. is a biopharmaceutical firm focused on the discovery and development of novel anti-infective drugs. The company's core research revolves around creating broad-spectrum medications that target various pathogens by inactivating pore-forming toxins. This is achieved by blocking the transmembrane pores formed by bacterial toxins, a method that has shown efficacy against toxins from pathogens like *Bacillus anthracis*, *Staphylococcus aureus*, and various *Clostridium* species.
The company’s primary therapeutic approach is based on the principle that simultaneously inhibiting bacterial growth with antibiotics and neutralizing toxin activity provides a more beneficial treatment outcome. A significant part of their research involves the use of cyclodextrin (CD) derivatives. By screening a library of these derivatives, the firm has successfully identified potent inhibitors for toxins produced by several dangerous bacteria, including those responsible for anthrax. This strategy leverages the structural symmetry between the per-substituted cyclodextrins and the target toxin pores to achieve highly efficient inhibitor selection. The research has demonstrated that both the symmetry and the size of the inhibitor and the pore are critical factors for effective blocking.
As a privately held, venture-capital-funded entity, Innovative Biologics operates on a small scale with an employee range of one to four individuals. The company has been an active participant in the Small Business Innovation Research (SBIR) program, securing its first award in 2007. It has received a total of $1,140,590 in SBIR funding, with $399,097 in Phase I and $741,493 in Phase II dollars, to advance its research programs.
Keywords: anti-infective drugs, bacterial toxins, pore-forming toxins, biopharmaceutical, antimicrobial, Bacillus anthracis, Staphylococcus aureus, Clostridium, cyclodextrin derivatives, transmembrane pores, broad-spectrum drugs, anti-toxin therapy, infectious disease treatment, SBIR recipient, drug discovery, biotechnology, pathogen inhibitors, anthrax treatment, microbial toxins, therapeutic development